minodronic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium metabolism regulator, pharmaceutical aid 4074 180064-38-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • minodronic acid
  • minodronic acid hydrate
  • recalbon
  • minodronate
  • YM-529
  • YM529
  • Molecular weight: 322.15
  • Formula: C9H12N2O7P2
  • CLOGP: -0.24
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 5
  • TPSA: 152.59
  • ALOGS: -1.57
  • ROTB: 4

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 0.01 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
July 11, 2011 PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis of jaw 78.40 34.28 27 991 35096 63452908
Atypical femur fracture 73.07 34.28 17 1001 5355 63482649
Hepatic function abnormal 51.06 34.28 20 998 37122 63450882
Spinal compression fracture 48.07 34.28 15 1003 14268 63473736
Upper respiratory tract inflammation 39.72 34.28 9 1009 2514 63485490

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis of jaw 84.28 32.42 31 1407 43195 79699755
Atypical femur fracture 66.45 32.42 16 1422 5173 79737777
Hepatic function abnormal 59.13 32.42 28 1410 73079 79669871
Spinal compression fracture 51.71 32.42 17 1421 16941 79726009
Upper respiratory tract inflammation 39.34 32.42 10 1428 4025 79738925
Interstitial lung disease 37.47 32.42 24 1414 112576 79630374

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Osteoporosis indication 64859006 DOID:11476




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.11 acidic
pKa2 6.18 acidic
pKa3 7.16 acidic
pKa4 10.96 acidic
pKa5 11.56 acidic
pKa6 5.65 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Farnesyl pyrophosphate synthase Enzyme IC50 8.52 CHEMBL
Geranylgeranyl pyrophosphate synthase Enzyme Ki 5.74 CHEMBL
Farnesyl diphosphate synthase Enzyme IC50 5.96 CHEMBL
Geranylgeranyl pyrophosphate synthase Enzyme Ki 6.89 CHEMBL

External reference:

IDSource
D09198 KEGG_DRUG
C2825721 UMLSCUI
M0N PDB_CHEM_ID
CHEMBL319144 ChEMBL_ID
DB06548 DRUGBANK_ID
130956 PUBCHEM_CID
3164 IUPHAR_LIGAND_ID
C087958 MESH_SUPPLEMENTAL_RECORD_UI
7651 INN_ID
40SGR63TGL UNII

Pharmaceutical products:

None